AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33231487
Drug: ACE-I/ARB therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-I/ARB therapy during hospitalization
Trial: 33234651
Drug: Serological tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serological tests for COVID-19 (IgM and IgG antibodies)
Trial: 33234651
Drug: Measurement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement of IgM and IgG antibodies
Trial: 33234662
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tumour infiltrating lymphocytes (TIL) and anti-PD-1
Trial: 33234662
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of TIL, pegylated-interferon-alpha (PEG-IFNa) and anti-PD-1
Trial: 33237534
Drug: INL-001 implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INL-001 implants (3 implants, each containing 100 mg bupivacaine HCl)
Trial: 33237534
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine HCl infiltration (175 mg)
Trial: 33239226
Drug: 1-dose Havrix
RxNorm normalized name: Havrix
DrugBank: Hepatitis A Vaccine (DB10989)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-dose Havrix vaccine
Trial: 33239226
Drug: 2-dose Havrix
RxNorm normalized name: Havrix
DrugBank: Hepatitis A Vaccine (DB10989)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose Havrix vaccine
Trial: 33239228
Drug: qHPV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: qHPV vaccine (3 doses on Day 1, Month 2, Month 6)
Trial: 33239899
Drug: Insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance defined by Homeostatic Model Assessment for insulin-resistance cut-offs that accommodated pubertal and gender differences.
Trial: 33239899
Drug: Anthropometric, metabolic,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthropometric, metabolic, intake-related variables, and 55 single nucleotide polymorphisms related to NAFLD and choline metabolism were evaluated.
Trial: 33240121
Drug: Transcranial Direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial Direct Current Stimulation (tDCS) as an add-on treatment to Cognitive-Behavior Therapy (CBT)
Trial: 33240257
Drug: Western Equine
RxNorm normalized name: Western equine encephalitis virus Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western Equine Encephalitis Vaccine (WEEV; WEE TSI-GSD 210)
Trial: 33240282
Drug: IO103 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IO103 vaccine with Montanide ISA 51 adjuvant, administered subcutaneously up to fifteen times during 1 year.
Trial: 33242065
Drug: PAR2 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAR2 antibody (MEDI0618)
Trial: 33242065
Drug: AZ8838 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZ8838 and AZ3451 (non-peptide small molecule antagonists)
Trial: 33242065
Drug: PAR2 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAR2 antibody (Fab3949)
Trial: 33242457
Drug: Nevirapine dosed
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine dosed at 6 mg/kg twice daily for term neonates or 4 mg/kg twice daily for 1 week and 6 mg/kg twice daily thereafter for preterm neonates.
Trial: 33242536
Drug: Olaparib for
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib for up to 10 weeks before chemotherapy
Trial: 33243149
Drug: Intrathecal hyperbaric
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal hyperbaric prilocaine (35 to 50 mg) co-administered with 2.5 mcg of sufentanil and 100 mcg of morphine
Trial: 33243149
Drug: Intrathecal hyperbaric
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal hyperbaric prilocaine with sufentanil and morphine
Trial: 33243251
Drug: Thrombospondin 1
RxNorm normalized name: Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs
DrugBank: Apadamtase alfa (DB15164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombospondin 1 (TSP1) treatment
Trial: 33244711
Drug: Netarsudil ophthalmic
RxNorm normalized name: netarsudil ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netarsudil ophthalmic solution 0.02% (n=8)
Trial: 33246388
Drug: Urban Zen
RxNorm normalized name: Geum urbanum root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urban Zen Integrative Therapy (UZIT)
Trial: 33246973
Drug: Deoxycytidine and
RxNorm normalized name: deoxycytidine
DrugBank: 2'-Deoxycytidine (DB02594)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deoxycytidine and deoxythymidine therapy
Trial: 33247014
Drug: Topical or
RxNorm normalized name: aloe vera topical oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical or systemic treatments for atopic dermatitis (AD)
Trial: 33248442
Drug: Lobectomy/Ishtmusectomy (L/I)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobectomy/Ishtmusectomy (L/I)
Trial: 33248962
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 2DE-LVEF or LVESVi and strain
Trial: 33249200
Drug: ICD/cardiac resynchronization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD/cardiac resynchronization therapy - defibrillator replacement
Trial: 33249636
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment for 16 weeks
Trial: 33249802
Drug: UST 130
RxNorm normalized name: ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: UST 130 mg
Trial: 33249802
Drug: UST 6
RxNorm normalized name: Ustell
DrugBank: Phenyl salicylate (DB11071)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UST 6 mg/kg
Trial: 33249802
Drug: UST 90
RxNorm normalized name: ustekinumab 90 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UST 90 mg q12w
Trial: 33249802
Drug: UST 90
RxNorm normalized name: ustekinumab 90 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UST 90 mg q8w
Trial: 33250788
Drug: Behavioral paradigms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral paradigms to facilitate treatment development
Trial: 33251516
Drug: Parenteral ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral ascorbic acid (1,500 mg), hydrocortisone (50 mg), and thiamine (100 mg) every 6 hours for 4 days
Trial: 33251691
Drug: Eculizumab (nine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab (nine infusions during the first 2 months posttransplant)
Trial: 33251774
Drug: Drug-coated balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-coated balloon (DCB) treatment with non-flow limiting dissection
Trial: 33251774
Drug: Drug-coated balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-coated balloon (DCB) treatment with flow limiting dissection
Trial: 33252292
Drug: IVF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVF treatment interrupted or postponed due to COVID-19
Trial: 33252347
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of BCTs and PSD principles
Trial: 33253641
Drug: Intravesical nadofaragene
RxNorm normalized name: Nadofaragene firadenovec
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical nadofaragene firadenovec (75 mL dose, 3×10^11 viral particles)
Trial: 33253997
Drug: Cabozantinib, median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib, median average daily dose 40.0 mg, treatment duration median 7.6 months
Trial: 33253997
Drug: Cabozantinib initiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib initiation at 60 mg/day
Trial: 33256377
Drug: Eltrombopag (EPAG)
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eltrombopag (EPAG) 50 mg/day to a maximum of 150 mg/day for 16 weeks
Trial: 33256777
Drug: Infants born
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants born weighing < 1000 g
Trial: 33256777
Drug: Infants born
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants born weighing 1000-1499 g
Trial: 33256777
Drug: Infants born
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants born weighing 1500-2499 g
Trial: 33256782
Drug: Babies born
RxNorm normalized name: Formula, Infant Oral Liquid [ENFAMIL ENFACARE FOR BABIES BORN PREMATURELY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Babies born weighing ≥ 2500 g
Trial: 33256829
Drug: Bevacizumab 15
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15 mg/kg IV on cycle 1 day 1 and carboplatin IV AUC=5 on cycle 1 day 8; trastuzumab for HER2-positive patients
Trial: 33257977
Drug: First-line chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line chemotherapy with fluoropyrimidine, oxaliplatin, and bevacizumab
Trial: 33258792
Drug: mobile-assisted cognitive
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mobile-assisted cognitive behavioral therapy for negative symptoms (mCBTn)
Trial: 33259032
Drug: Checkpoint inhibition
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Checkpoint inhibition therapy using monoclonal antibodies against PD-1 or PD-L1
Trial: 33259326
Drug: Peer support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer support group intervention facilitated by PSWs (10 weekly 90-minute online workshops)
Trial: 33259589
Drug: Umbralisib (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umbralisib (800 mg/d)
Trial: 33259782
Drug: TDS (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDS (120 µg/day levonorgestrel and 30 µg/day ethinyl estradiol)
Trial: 33259921
Drug: Epicutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epicutaneous immunotherapy for peanut allergy
Trial: 33259932
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of androgen deprivation therapy (ADT) concurrent with abiraterone acetate plus prednisone (AAP) once daily and radiation therapy (RT) to prostate and seminal vesicles
Trial: 33259932
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of ADT concurrent with AAP and RT
Trial: 33262134
Drug: HPN536 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPN536 (doses ranging from 0.1 to 10 mg/kg)
Trial: 33262641
Drug: Tolperisone 50
RxNorm normalized name: tolperisone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolperisone 50 mg TID
Trial: 33262641
Drug: Tolperisone 100
RxNorm normalized name: tolperisone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolperisone 100 mg TID
Trial: 33262641
Drug: Tolperisone 150
RxNorm normalized name: tolperisone
DrugBank: Tolperisone (DB06264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolperisone 150 mg TID
Trial: 33262641
Drug: Tolperisone 200
RxNorm normalized name: tolperisone
DrugBank: Tolperisone (DB06264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolperisone 200 mg TID
Trial: 33264119
Drug: Norepinephrine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine administered during anesthesia (μg·kg-1 30 min-1)
Trial: 33267919
Drug: Cognitive-behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavior therapy (CBT-E)
Trial: 33267959
Drug: Follitropin delta
RxNorm normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follitropin delta coadministered with HP-hMG (dosage adjustments confined to HP-hMG only)
Trial: 33268029
Drug: Haploidentical natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haploidentical natural killer (NK) cell infusions after autologous stem cell transplant (ASCT)
Trial: 33268029
Drug: Haploidentical natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haploidentical natural killer (NK) cell infusions
Trial: 33268421
Drug: PharMoG team
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PharMoG team intervention (clinical medication review)
Trial: 33269549
Drug: LENT index
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LENT index (combination of LE index and NT-proBNP levels)
Trial: 33269625
Drug: linagliptin add-on
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: linagliptin add-on therapy
Trial: 33270816
Drug: leukemia-specific T
RxNorm normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: leukemia-specific T cells (mLSTs) administered at escalating doses (0.5 to 10 × 10^7 cells per square meter)
Trial: 33270832
Drug: Eculizumab discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab discontinuation
Trial: 33271094
Drug: GX-188E therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GX-188E therapeutic DNA vaccine plus pembrolizumab
Trial: 33272131
Drug: PF-05230907 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-05230907 at 30 μg/kg
Trial: 33272131
Drug: PF-05230907 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-05230907 at doses ranging from 5 to 30 μg/kg
Trial: 33272982
Drug: Nivolumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) combined with Infliximab (5 mg/kg)
Trial: 33272982
Drug: Nivolumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) combined with Certolizumab
Trial: 33273485
Drug: Continuous weekly
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous weekly DBS CRP data
Trial: 33275104
Drug: Twitter +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twitter + Fitbit treatment group
Trial: 33275278
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium
Trial: 33275278
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin B
Trial: 33275278
Drug: Oral calcium-vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral calcium-vitamin D
Trial: 33276117
Drug: Type 2
RxNorm normalized name: Type 2 H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type 2 inflammation treatment
Trial: 33276302
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment for ICAD
Trial: 33276423
Drug: two-visit primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two-visit primary vaccination schedule (two intradermal 0.1 mL rabies vaccine doses on day 0 and 7)
Trial: 33276423
Drug: three-visit primary
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three-visit primary vaccination schedule (single intradermal 0.1 mL dose on day 0, 7, and 28)
Trial: 33277427
Drug: Intrathecal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal administration of autologous mesenchymal stem cell-derived neural progenitors (MSC-NPs), 3 injections spaced 3 months apart.
Trial: 33277427
Drug: Intrathecal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal administration of autologous mesenchymal stem cell-derived neural progenitors (MSC-NPs).
Trial: 33277620
Drug: VIDL induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIDL induction chemotherapy (4 cycles)
Trial: 33277620
Drug: VIDL induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIDL induction chemotherapy
Trial: 33277913
Drug: Tacrolimus-based immunosuppressive
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus-based immunosuppressive therapy (73.7% of recipients)
Trial: 33277913
Drug: Ciclosporin-based immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin-based immunosuppressive therapy (24.3% of recipients)
Trial: 33277913
Drug: Tacrolimus-based immunosuppressive
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus-based immunosuppressive therapy
Trial: 33277913
Drug: Ciclosporin-based immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin-based immunosuppressive therapy
Trial: 33278077
Drug: Cell-based immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell-based immunotherapy
Trial: 33278077
Drug: Cell-based therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell-based therapies
Trial: 33278125
Drug: High-dose synthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose synthetic ACTH
Trial: 33278125
Drug: Low-dose synthetic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose synthetic ACTH
Trial: 33278125
Drug: New hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New hydrocortisone formulations and delivery methods
Trial: 33278125
Drug: Medications in
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications in combination with hydrocortisone
Trial: 33279887
Drug: Panobinostat (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat (20 mg oral, weeks 1 and 2), Bortezomib (1.3 mg/m2 subcutaneous, days 1, 4, 8, and 11), Dexamethasone (20 mg oral, day of and the day following bortezomib administration) for 8 cycles (24 weeks)
Trial: 33281736
Drug: Normobaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normobaric oxygen (NBO) at 5-8 L/min, 1 hour per session, 3 times daily
Trial: 33281950
Drug: Preoperative endocrine
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative endocrine therapy (ET) for 3 (±1) weeks
Trial: 33282202
Drug: LIQ861 (dry-powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIQ861 (dry-powder inhaled formulation of treprostinil) at doses of 25, 50, 75, 100, 125, and 150 mcg
Trial: 33553366
Drug: Neoadjuvant toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant toripalimab plus chemotherapy
Trial: 33282726
Drug: Anlotinib treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib treatment
Trial: 33283990
Drug: BCH-BB694 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: BCH-BB694 gene therapy (infusion of autologous CD34+ cells transduced with BCH-BB694 lentiviral vector)
Trial: 33284423
Drug: Ixekizumab 80-mg
RxNorm normalized name: ixekizumab 80 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab 80-mg every 2 weeks (Q2W)
Trial: 33284423
Drug: Ixekizumab 80-mg
RxNorm normalized name: ixekizumab 80 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab 80-mg every 4 weeks (Q4W)
Trial: 33287189
Drug: Pembrolizumab, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab, dosage and duration not available
Trial: 33287583
Drug: Regional differences
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional differences in treatment approaches
Trial: 33287722
Drug: LdT (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LdT (600 mg/day) for 24 weeks, followed by LdT monotherapy until 104 weeks
Trial: 33288587
Drug: CCR5 inhibition
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCR5 inhibition treatment
Trial: 33288749
Drug: Durvalumab (anti-PD-L1)
RxNorm normalized name: Protease-activated anti-pd-l1 antibody prodrug cx-072
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab (anti-PD-L1) combined with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in cohort A
Trial: 33289590
Drug: Hypomethylating agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypomethylating agent (HMA) guadecitabine